AR050617A1 - Derivados de pirimidin sulfonamidas como moduladores de receptores de quimioquinas - Google Patents

Derivados de pirimidin sulfonamidas como moduladores de receptores de quimioquinas

Info

Publication number
AR050617A1
AR050617A1 ARP050103584A ARP050103584A AR050617A1 AR 050617 A1 AR050617 A1 AR 050617A1 AR P050103584 A ARP050103584 A AR P050103584A AR P050103584 A ARP050103584 A AR P050103584A AR 050617 A1 AR050617 A1 AR 050617A1
Authority
AR
Argentina
Prior art keywords
phenyl
alkyl
group
substituents independently
independently selected
Prior art date
Application number
ARP050103584A
Other languages
English (en)
Inventor
David Cheshire
Rhona Jane Cox
Premji Meghani
Cherylin Francis Preston
Neal Michael Smith
Jeffrey Paul Stonehause
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35549576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050617(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0419235A external-priority patent/GB0419235D0/en
Priority claimed from GB0502544A external-priority patent/GB0502544D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR050617A1 publication Critical patent/AR050617A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/58—Two sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)

Abstract

Método de preparacion y composiciones farmacéuticas que los contienen, y usos para tratamiento de enfermedades y trastornos mediados por quimioquinas. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) en donde R1 es un grupo seleccionado entre C3-7 carbociclilo, C1-8 alquilo, C2-6 alquenilo y C2-6 alquinilo; en el grupo está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre fluoro, nitrilo, -OR4, -NR5R6, -CONR5R6, - COOR7, -NR8COR9, -SR10, -SO2R10, -SO2NR5R6, -NR8SO2R9, fenilo o heteroarilo; en donde fenilo y heteroarilo están opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, ciano, nitro, -OR4, -NR5R6, - CONR5R6, -COOR7, -NR8COR9, -SR10, -SO2R10, -SO2NR5R6, -NR8SO2R9, alquilo C1-6 y trifluorometilo; X es -CH2-, un enlace, O, S, sulfoxido, o sulfona; R2 es C3-7 carbociclilo, opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre: fluoro, -OR4, -NR5R6, -CONR5R6, -COOR7, -NR8COR9, -SR10, -SO2R10, -SO2NR5R6, -NR8SO2R9; o R2 es un anillo de 3 a 8 miembros que contiene opcionalmente 1, 2 o 3 átomos seleccionados entre O, S, -NR8 y con lo cual el anillo está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre C1-3 alquilo, fluoro, -OR4, -NR5R6, -CONR5R6, -COOR7, -NR8COR9, -SR10, -SO2R10, -SO2NR5R6, -NR8SO2R9, o R2 es fenilo o heteroarilo, cada uno de los cuales está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, ciano, nitro, -OR4, -NR5R6, -CONR5R6, -COOR7, -NR8COR9, -SR10, -SO2R10, -SO2NR5R6, -NR8SO2R9, C1-6 alquilo y trifluorometilo; o R2 es un grupo seleccionado entre alquilo C1-8, alquenilo C2-6 o alquinilo C2-6 en donde el grupo está sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre hidroxi, amino, C1-6 alcoxi, C1-6 alquilamino, di(C1-6 alquil)amino, N-(C1-6 alquil)-N-(fenil)amino, N-C1-6 alquilcarbamoilo, N,N-di(C1-6 alquil)carbamoílo, N-(C1-6 alquil)-N-(fenil)carbamoílo, carboxi, fenoxicarbonilo, -NR8COR9, -SO2R10, -SO2NR5R6, --NR8SO2R9 y -CONR5R6; R3 es trifluorometilo o un grupo -NR5R6, o R3 es fenilo, naptilo, heteroarilo monocíclico o bicíclico en donde un heteroátomo puede ser parcial o totalmente saturado y uno o más átomos de carbono del anillo pueden formar un grupo carbonilo, y en donde cada grupo fenilo o heteroarilo está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, ciano, nitro, fenilo, heteroarilo, -OR4, -NR5R6, -CONR5R6, -COR7, -COR20, --COOR7, -NR8COR9, -SR10, -SO2R10, -SO2NR5R6, -NR8SO2R9, trifluorometilo o C1-6 alquilo [opcionalmente sustituido adicionalmente por 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, ciano, nitro, -OR20, -COOR20, -COR20, -NR18R19, -NR18COR19, -SO2R20, -SO2NR18R19, -NR18SO2R19, fenilo o heteroarilo monocíclico o bicíclico, en donde un anillo heterocíclico puede estar parcial o totalmente saturado; y en donde cada grupo fenilo o heteroarilo está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, ciano, nitro, -OR20, -NR5R6, -CONR5R6, -COR7, -COOR7, -NR8COR9, -SR10, -SO2R10, -SO2NR5R6, -NR8SO2R9, heteroarilo, C1-6 alquilo (opcionalmente sustituido adicionalmente por 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, ciano, nitro, -OR20, -COOR20, -COR20, -NR18R19, -CONR18R19, NR18COR19, -SO2R20, -SO2NR18R19, -NR18SO2R19, o R3 es un grupo seleccionado entre C3-7 carbociclilo, C1-8 alquilo, C2-6 alquenilo y C2-6 alquinilo con lo cual el grupo está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, -OR4, -NR5R6, -CONR5R6, -COR7, -COOR7, -NR8COR9, -SR10, -SO2R10, -SO2NR5R6, -NR8SO2R9, fenilo o heteroarilo monocíclico o bicíclico, en donde un anillo heterocíclico puede estar parcial o totalmente saturado; y en donde cada grupo fenilo o heteroarilo monocíclico o bicíclico está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, ciano, nitro, -OR4, -NR5R6, -CONR5R6, -COR7, -COOR7, -NR8COR9, -SR10, -SO2R10, -SO2NR5R6, -NR8SO2R9, C1-6 alquilo, o trifluorometilo; R4 es H o un grupo seleccionado entre alquilo C1-6 y fenilo, en el grupo está opcionalmente sustituido con 1 o 2 sustituyentes seleccionados en forma independiente entre halo, fenilo, -OR11 y -NR12R13; R5 y R6 son de forma independiente H o un grupo seleccionado entre C1-6 alquilo y fenilo y heteroarilo monocíclico o bicíclico, en donde un anillo heterocíclico puede estar parcial o totalmente saturado; en el grupo está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, fenilo, -OR14, -NR15R16, -COOR14, -CONR15R16, -NR15COR16, -SO2R10, -SO2NR15R16 y NR15SO2R16; o R5 y R6 junto con el átomo de N al cual están unidos forman un sistema de anillo heterocíclico de 4 a 7 miembros que contiene opcionalmente un heteroátomo adicional seleccionado entre O, -SO(n)- (donde n = 0, 1 o 2) y átomos de N, en el cual el anillo está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre fenilo, heteroarilo, -OR14, -COR20, -COOR14, -NR15R16, -CONR15R16, -NR15COR16, -SO2R10, -SO2NR15R16, - NR15SO2R16 o C1-6 alquilo (opcionalmente sustituido adicionalmente por 1, 2 o 3 sustituyentes seleccionados en forma independiente entre grupos halo, -NR15R16 y -OR17 o ciano, nitro, -OR20, -COOR20, -COR20, -NR18R19, -CONR18R19, -NR18COR19, -SO2R20, -SO2NR18R19, -NR18SO2R19); R10 es H o un grupo seleccionado entre C1-6 alquilo o fenilo, en el grupo está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, -OR17 y -NR15R16; y cada uno de R7, R8, R9,R11, R12, R13, R14, R15, R16, R17 es en forma independiente H, C1-6 alquilo o fenilo. R18, R19, y R20 son H o un grupo seleccionado entre C1-6 alquilo o heteroarilo (en donde un anillo heterocíclico puede estar parcial o totalmente saturado) o fenilo, en el grupo está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, nitro, -CN, -OR4, -NR8R9, -CONR8R9, -COR7, -COOR7, -NR8COR9, -SR10, -SO2R10, -SO2NR8R9, -NR8SO2R9, C1-6 alquilo o heteroarilo o una sal aceptable para uso farmacéutico, solvato o un éster hidrolizable en vivo del mismo.
ARP050103584A 2004-08-28 2005-08-26 Derivados de pirimidin sulfonamidas como moduladores de receptores de quimioquinas AR050617A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0419235A GB0419235D0 (en) 2004-08-28 2004-08-28 Compounds
GB0502544A GB0502544D0 (en) 2005-02-08 2005-02-08 Compounds

Publications (1)

Publication Number Publication Date
AR050617A1 true AR050617A1 (es) 2006-11-08

Family

ID=35549576

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103584A AR050617A1 (es) 2004-08-28 2005-08-26 Derivados de pirimidin sulfonamidas como moduladores de receptores de quimioquinas

Country Status (28)

Country Link
US (5) US7838675B2 (es)
EP (3) EP2301933A1 (es)
JP (3) JP4795352B2 (es)
KR (1) KR101280095B1 (es)
CN (1) CN102796081B (es)
AR (1) AR050617A1 (es)
AU (1) AU2005279045B2 (es)
BR (1) BRPI0514735B8 (es)
CA (1) CA2578441C (es)
CY (1) CY1114803T1 (es)
DK (1) DK1809624T3 (es)
ES (1) ES2442678T3 (es)
HK (1) HK1103742A1 (es)
HR (1) HRP20140023T1 (es)
IL (1) IL181241A0 (es)
ME (1) ME01620B (es)
MX (1) MX2007002240A (es)
MY (1) MY148125A (es)
NO (1) NO338749B1 (es)
NZ (1) NZ553335A (es)
PL (1) PL1809624T3 (es)
PT (1) PT1809624E (es)
RS (1) RS53145B (es)
RU (1) RU2408587C2 (es)
SI (1) SI1809624T1 (es)
TW (1) TWI369983B (es)
UY (1) UY29085A1 (es)
WO (1) WO2006024823A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262286A (ja) * 1985-09-13 1987-03-18 株式会社東芝 沸騰水型原子炉炉心
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
JP2007538054A (ja) 2004-05-19 2007-12-27 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング 肥満および関係する病気の予防または治療のためのｎ−スルファモイル−ｎ′−アリールピペラジンを含有する薬剤
CN102796081B (zh) 2004-08-28 2015-04-22 阿斯利康(瑞典)有限公司 作为趋化因子受体调节剂的嘧啶磺酰胺衍生物
EP1891063B1 (en) 2005-05-10 2012-07-25 Vertex Pharmaceuticals, Inc. Bicyclic derivatives as modulators of ion channels
EP2099444A4 (en) 2006-12-14 2012-11-07 Nps Pharma Inc USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
WO2008135786A1 (en) * 2007-05-04 2008-11-13 Astrazeneca Ab Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
RU2011101661A (ru) * 2008-07-16 2012-08-27 Астразенека Аб (Se) Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
US8748603B2 (en) * 2010-07-13 2014-06-10 Astrazeneca Ab Crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]THIO]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
JP6006308B2 (ja) * 2011-07-12 2016-10-12 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ ケモカイン受容体モジュレーターとしてのｎ−（６−（（２ｒ，３ｓ）−３，４−ジヒドロキシブタン−２−イルオキシ）−２−（４−フルオロベンジルチオ）ピリミジン−４−イル）−３−メチルアゼチジン−１−スルホンアミド
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
PL3263133T3 (pl) 2015-02-27 2020-10-05 Kyushu University, National University Corporation Związek pirydynonu i jego zastosowanie
CA3017345A1 (en) * 2016-03-11 2017-09-14 Ardea Biosciences, Inc. Cxcr-2 inhibitors for treating crystal arthropathy disorders
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
WO2023028077A1 (en) 2021-08-24 2023-03-02 Genentech, Inc. Sodium channel inhibitors and methods of designing same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540356A (en) * 1949-03-12 1951-02-06 Sharp & Dohme Inc Sulfonamide derivatives
GB866843A (en) * 1958-12-08 1961-05-03 Ici Ltd Sulphonamidopyrimidines
NL279406A (es) * 1961-06-16
NL302745A (es) 1962-12-29
US3457278A (en) * 1964-10-15 1969-07-22 Geigy Chem Corp Cyclopropyl-4-sulfanilamido-pyrimidines
US3452018A (en) * 1966-08-29 1969-06-24 American Home Prod 1 - (2 - substituted - 6 - arylsulfonamidopyrimidin - 4 - yl)pyridinium hydroxide inner salts
US3673184A (en) * 1970-09-02 1972-06-27 Dainippon Pharmaceutical Co Certain 2-substituted-5,8-dihydro-5-oxopyrido{8 2,3-d{9 pyrimidine-6-carboxylic acid derivatives
JPS61118372A (ja) 1984-11-12 1986-06-05 Nippon Mektron Ltd 新規ピリミジン誘導体およびその製造法
JPS6442295A (en) 1987-08-10 1989-02-14 Seiko Epson Corp Memory card mounting structure
JPH03197467A (ja) 1989-12-26 1991-08-28 Nippon Kayaku Co Ltd ピリミジノン誘導体その製法及びそれを有効成分とする殺虫・殺ダニ剤
WO1991015209A1 (en) 1990-03-30 1991-10-17 Merck & Co., Inc. Substituted pyrimidines, pyrimidinones and pyridopyrimidines
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
EP0880508B1 (en) 1996-02-13 2003-04-16 AstraZeneca AB Quinazoline derivatives as vegf inhibitors
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
IL137922A0 (en) 1998-02-17 2001-10-31 Tularik Inc Anti-viral pyrimidine derivatives
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU5108000A (en) 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
JP2003522191A (ja) 2000-02-11 2003-07-22 アストラゼネカ・アクチエボラーグ ケモカイン受容体活性のモジュレーターとしてのピリミジン化合物およびそれらの使用
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
BR0114082A (pt) 2000-09-25 2003-07-22 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
CA2465711A1 (en) * 2001-11-07 2003-05-15 F. Hoffmann-La Roche Ag Aminopyrimidines and pyridines
TWI328007B (en) 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
TWI314928B (en) 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
ES2295685T3 (es) 2002-08-24 2008-04-16 Astrazeneca Ab Derivados de pirimidina como moduladores de la actividad del receptor de quimioquinas.
CN102796081B (zh) 2004-08-28 2015-04-22 阿斯利康(瑞典)有限公司 作为趋化因子受体调节剂的嘧啶磺酰胺衍生物
RU2011101661A (ru) 2008-07-16 2012-08-27 Астразенека Аб (Se) Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний

Also Published As

Publication number Publication date
CN102796081A (zh) 2012-11-28
BRPI0514735B1 (pt) 2020-08-11
US20130012490A1 (en) 2013-01-10
AU2005279045A1 (en) 2006-03-09
NZ553335A (en) 2010-05-28
RU2408587C2 (ru) 2011-01-10
AU2005279045B2 (en) 2009-11-26
IL181241A0 (en) 2007-07-04
UY29085A1 (es) 2006-03-31
BRPI0514735B8 (pt) 2021-05-25
US20110124619A1 (en) 2011-05-26
US20120157431A1 (en) 2012-06-21
US20130203991A1 (en) 2013-08-08
HRP20140023T1 (hr) 2014-02-14
EP2301933A1 (en) 2011-03-30
MY148125A (en) 2013-02-28
SI1809624T1 (sl) 2014-02-28
JP5364735B2 (ja) 2013-12-11
CN102796081B (zh) 2015-04-22
JP2011084576A (ja) 2011-04-28
BRPI0514735A (pt) 2008-06-24
ES2442678T3 (es) 2014-02-12
US8410123B2 (en) 2013-04-02
ME01620B (me) 2014-09-20
MX2007002240A (es) 2007-04-20
DK1809624T3 (da) 2014-01-20
KR101280095B1 (ko) 2013-09-09
US8269002B2 (en) 2012-09-18
PT1809624E (pt) 2014-01-14
JP2013177447A (ja) 2013-09-09
NO338749B1 (no) 2016-10-17
CA2578441A1 (en) 2006-03-09
TWI369983B (en) 2012-08-11
KR20070046897A (ko) 2007-05-03
WO2006024823A1 (en) 2006-03-09
PL1809624T3 (pl) 2014-03-31
EP1809624B1 (en) 2013-11-20
CA2578441C (en) 2013-01-08
TW200612909A (en) 2006-05-01
NO20071594L (no) 2007-05-02
JP2008511597A (ja) 2008-04-17
RU2007106037A (ru) 2008-10-10
JP5730350B2 (ja) 2015-06-10
US7838675B2 (en) 2010-11-23
JP4795352B2 (ja) 2011-10-19
EP2311827A1 (en) 2011-04-20
RS53145B (en) 2014-06-30
US20080096860A1 (en) 2008-04-24
HK1103742A1 (en) 2007-12-28
EP1809624A1 (en) 2007-07-25
WO2006024823A9 (en) 2007-03-15
US8722883B2 (en) 2014-05-13
CY1114803T1 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
AR050617A1 (es) Derivados de pirimidin sulfonamidas como moduladores de receptores de quimioquinas
AR055303A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamento
AR079541A1 (es) Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms
AR040700A1 (es) Derivados de pirimidilsulfonamida como moduladores de receptores de quimioquinas
MA50065B1 (fr) Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53
AR037736A1 (es) Derivados de pirimidina como moduladores o inhibidores de la actividad del factor de crecimiento insulinico tipo 1 (igf-1r)
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR047098A1 (es) Derivados de arilanilina como agonistas del receptor adrenergico beta2
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
AR078535A1 (es) Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras
AR078786A1 (es) Derivados de la cromenona
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20081689A1 (es) Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas y su preparacion
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
AR068057A1 (es) Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio.
DE602006019221D1 (de) Von dopamin-d3-rezeptoren
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
PE20070069A1 (es) Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a
PE20060457A1 (es) Derivados de difenil eter como antagonistas de los receptores 5ht2
AR068466A1 (es) Cianoisoquinolina
PE20091811A1 (es) DERIVADOS DE IMIDAZOLIDINONA COMO INHIBIDORES DE 11b-HSD1

Legal Events

Date Code Title Description
FG Grant, registration